专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08785599B2 FcγRIIB—specific antibodies and methods of use thereof 有权
标题翻译： FcγRIIB特异性抗体及其使用方法
公开(公告)号：US08785599B2
公开(公告)日：2014-07-22
申请号：US11768852
申请日：2007-06-26
申请人： Leslie S. Johnson , Ling Huang , Robyn Gerena
发明人： Leslie S. Johnson , Ling Huang , Robyn Gerena
IPC分类号： C07K16/00 , C12P21/08 , A61K39/395 , A61K39/40 , C07K1/00
CPC分类号： C07K16/283 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/34 , C07K2317/52 , C07K2317/565 , C07K2317/732 , C07K2317/92
摘要： The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than the antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also provides the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.
摘要翻译：本发明涉及以比抗体或其片段更大的亲和力结合FcγRIIA，特别是人FcγRIIA的FcγRIIB特别是人FcγRIIB特异性结合的抗体或其片段。本发明还提供抗FcγRIIB抗体或其抗原结合片段作为治疗，预防，治疗或改善癌症，优选B细胞恶性肿瘤，特别是B细胞恶性肿瘤的单一药物治疗的用途细胞性慢性淋巴细胞白血病或非霍奇金淋巴瘤，自身免疫性疾病，炎症性疾病，IgE介导的过敏性疾病或其一种或多种症状。本发明提供了通过施用本发明的抗体来增强治疗性抗体的效应功能来增强治疗性抗体的治疗效果的方法。本发明还提供了通过施用本发明的抗体来增强疫苗组合物的功效的方法。

2. 发明申请

US20150023964A1 FcgammaRIIB-Specific Antibodies and Methods of Use Thereof 审中-公开
标题翻译： FcgammaRIIB特异性抗体及其使用方法
公开(公告)号：US20150023964A1
公开(公告)日：2015-01-22
申请号：US14331360
申请日：2014-07-15
申请人： Leslie S. Johnson , Ling Huang , Robyn Gerena
发明人： Leslie S. Johnson , Ling Huang , Robyn Gerena
IPC分类号： C07K16/28 , A61K45/06 , A61K39/395
CPC分类号： C07K16/283 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/34 , C07K2317/52 , C07K2317/565 , C07K2317/732 , C07K2317/92
摘要： The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than the antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also provides the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.
摘要翻译：本发明涉及以比抗体或其片段更大的亲和力结合FcγRIIA，特别是人FcγRIIA的FcγRIIB特别是人FcγRIIB特异性结合的抗体或其片段。本发明还提供抗FcγRIIB抗体或其抗原结合片段作为治疗，预防，治疗或改善癌症，优选B细胞恶性肿瘤，特别是B细胞恶性肿瘤的单一药物治疗的用途细胞性慢性淋巴细胞白血病或非霍奇金淋巴瘤，自身免疫性疾病，炎症性疾病，IgE介导的过敏性疾病或其一种或多种症状。本发明提供了通过施用本发明的抗体来增强治疗性抗体的效应功能来增强治疗性抗体的治疗效果的方法。本发明还提供了通过施用本发明的抗体来增强疫苗组合物的功效的方法。

3. 发明申请

US20080044429A1 Fc.gamma.RIIB-Specific Antibodies and Methods of Use Thereof 有权
标题翻译： Fc.gamma.RIIB特异性抗体及其使用方法
公开(公告)号：US20080044429A1
公开(公告)日：2008-02-21
申请号：US11768852
申请日：2007-06-26
申请人： Leslie Johnson , Ling Huang , Robyn Gerena
发明人： Leslie Johnson , Ling Huang , Robyn Gerena
IPC分类号： A61K39/395 , A61P35/00 , C07H21/00 , C07K16/00 , C07K16/30 , C07K7/06 , C07K7/08 , C12N1/00 , C12N15/63 , C12P21/02
CPC分类号： C07K16/283 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/34 , C07K2317/52 , C07K2317/565 , C07K2317/732 , C07K2317/92
摘要： The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also provides the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.
摘要翻译：本发明涉及以比所述抗体或其片段更大的亲和力结合FcγRIIA，特别是人FcγRIIA的FcγRIIB特别是人FcγRIIB特异性结合的抗体或其片段。本发明还提供抗FcγRIIB抗体或其抗原结合片段作为单一药物治疗用于治疗，预防，治疗或改善癌症，优选B细胞恶性肿瘤，特别是B细胞细胞性慢性淋巴细胞白血病或非霍奇金淋巴瘤，自身免疫性疾病，炎症性疾病，IgE介导的过敏性疾病或其一种或多种症状。本发明提供了通过施用本发明的抗体来增强治疗性抗体的效应功能来增强治疗性抗体的治疗效果的方法。本发明还提供了通过施用本发明的抗体来增强疫苗组合物的功效的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式